GlassScriptPhysician profile
Christine B Mitchell
NPI 1295219145
$11,590.22
in general payments reported to CMS, 2019-2025
42 companies · $1,910 in 2025
The $1,910 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,636 · 2022: $2,591 · 2023: $2,228 · 2024: $2,225 · 2025: $1,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,363.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $1,386.38 | 2021-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $1,097.50 | 2021-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $992.82 | 2021-2025 | |
| Novo Nordisk INC | $920.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Travere Therapeutics, INC. | $649.07 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $541.07 | 2021-2025 | Acthar |
| Amgen INC. | $537.54 | 2021-2025 | Krystexxa, Tavneos, Repatha |
| Corcept Therapeutics | $529.66 | 2021-2025 | Korlym |
| Abbott Laboratories | $445.93 | 2021-2023 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $431.96 | 2021 | |
| Novartis Pharmaceuticals Corporation | $429.62 | 2024-2025 | |
| Lilly USA, LLC | $416.03 | 2021-2024 | Mounjaro, Jardiance |
| Horizon Therapeutics Plc | $404.53 | 2021-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $373.95 | 2022-2025 | Tarpeyo |
| Mannkind Corporation | $372.23 | 2022-2025 | Afrezza |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.